A Study Evaluated the Safety and Efficacy of BAT6026 in Patients With Moderate to Severe Atopic Dermatitis Phase I/II Clinical Study
Latest Information Update: 13 Feb 2026
At a glance
- Drugs BAT 6026 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Bio-Thera Solutions
Most Recent Events
- 10 Feb 2026 Planned End Date changed from 15 Oct 2025 to 30 Jun 2026.
- 10 Feb 2026 Planned primary completion date changed from 1 Feb 2025 to 1 Jun 2026.
- 10 Feb 2026 Status changed from recruiting to active, no longer recruiting.